Clinical Trial Update: Efficacy and Safety of Aflibercept in Patients With Neovascular Age-related Macular Degeneration [Phase 3]

View source ↗

Summary

Phase 3 trial update on aflibercept for neovascular age-related macular degeneration assessing efficacy and safety.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration
• Neovascular Age-related Macular Degeneration

Drugs mentioned

• Aflibercept (Aflibercept)

Snippet

Sponsor: Cinnagen | Conditions: Age-Related Macular Degeneration, Neovascular Age-related Macular Degeneration | Phase 3 | Status: COMPLETED